Basit öğe kaydını göster

dc.contributor.authorTunali, Sevim
dc.contributor.authorCan, Ayşe
dc.contributor.authorYanardag, Refiye
dc.contributor.authorCelik, Ertan
dc.contributor.authorGezginci-Oktayoglu, Selda
dc.contributor.authorBOLKENT, Şehnaz
dc.date.accessioned2021-12-10T13:09:15Z
dc.date.available2021-12-10T13:09:15Z
dc.date.issued2021
dc.identifier.citationCelik E., Tunali S., Gezginci-Oktayoglu S., BOLKENT Ş., Can A., Yanardag R., "Vitamin U prevents valproic acid-induced liver injury through supporting enzymatic antioxidant system and increasing hepatocyte proliferation triggered by inflammation and apoptosis", TOXICOLOGY MECHANISMS AND METHODS, cilt.31, sa.8, ss.600-608, 2021
dc.identifier.issn1537-6516
dc.identifier.othervv_1032021
dc.identifier.otherav_f245698b-b434-4829-8429-ab30c7c21acd
dc.identifier.urihttp://hdl.handle.net/20.500.12627/175532
dc.identifier.urihttps://doi.org/10.1080/15376516.2021.1943089
dc.description.abstractThe aim of this study was to investigate the cellular mechanisms that cause valproic acid (VPA)-induced liver damage and the therapeutic effect of Vitamin U (Vit U) on these mechanisms. Female Sprague Dawley rats were randomly divided into four groups: intact control animals, animals that received Vit U (50 mg/kg/day), animals given VPA (500 mg/kg/day), and animals given both VPA and Vit U. The rats in the Vit U + VPA group were administered Vit U by gavage an hour before VPA administration every day for 15 days. Liver tissues were evaluated through histopathological, biochemical, immunohistochemical, and Western blotting techniques. Administration of Vit U with VPA resulted in (i) prevention of histopathological changes caused by VPA; (ii) blockage of the decrease in catalase (CAT), glutathione reductase (GR), glutathione peroxidase (GPx), and superoxide dismutase (SOD) activities; prevention of the elevation in gamma-glutamyl transferase (GGT) activity and advanced oxidation protein products (AOPP) level; (iii) increased in the levels of interleukin-1 beta (IL-1 beta), active caspase-3, and cytoplasmic cytochrome c; (iv) increase in cleaved poly (ADP-ribose) polymerase (PARP) level and decrease in LC3B (II/I) ratio; (v) increase in the number of proliferating cells nuclear antigen (PCNA) positive hepatocytes. These findings show that Vit U prevents liver damage caused by VPA through increasing the antioxidant enzyme capacity and hepatocyte proliferation by triggering inflammation and apoptosis. These findings suggest that Vit U provides its protective effects against VPA-induced liver damage by stimulating homeostasis and regeneration.
dc.language.isoeng
dc.subjectFarmasötik Toksikoloji
dc.subjectYaşam Bilimleri
dc.subjectTemel Bilimler
dc.subjectToxicology
dc.subjectPharmacology, Toxicology and Pharmaceutics (miscellaneous)
dc.subjectHealth, Toxicology and Mutagenesis
dc.subjectPhysical Sciences
dc.subjectLife Sciences
dc.subjectSağlık Bilimleri
dc.subjectEczacılık
dc.subjectMeslek Bilimleri
dc.subjectYaşam Bilimleri (LIFE)
dc.subjectFarmakoloji ve Toksikoloji
dc.subjectTOKSİKOLOJİ
dc.titleVitamin U prevents valproic acid-induced liver injury through supporting enzymatic antioxidant system and increasing hepatocyte proliferation triggered by inflammation and apoptosis
dc.typeMakale
dc.relation.journalTOXICOLOGY MECHANISMS AND METHODS
dc.contributor.departmentİstanbul Üniversitesi , ,
dc.identifier.volume31
dc.identifier.issue8
dc.identifier.startpage600
dc.identifier.endpage608
dc.contributor.firstauthorID2717545


Bu öğenin dosyaları:

DosyalarBoyutBiçimGöster

Bu öğe ile ilişkili dosya yok.

Bu öğe aşağıdaki koleksiyon(lar)da görünmektedir.

Basit öğe kaydını göster